Rufinamide
Back to searchMolecule Structure
Scientific Name
Rufinamide
Description of the Drug
Rufinamide is an antiepileptic drug used as adjunctive therapy to treat seizures associated with Lennox-Gastaut Syndrome (LGS).
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB06201
http://www.drugbank.ca/drugs/DB06201
Brand Name(s)
Banzel, Inovelon, Rufinamide
Company Owner(s)
Alkem Laboratories Ltd, Eisai Inc, Hetero Labs Ltd Unit Iii, Glenmark Pharmaceuticals Ltd, Mylan Pharmaceuticals Inc, Bionpharma Inc, Hikma Pharmaceuticals Usa Inc, Hikma Pharmaceuticals International Ltd, Lupin Ltd
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Sodium channel alpha subunit | PROTEIN FAMILY | BLOCKER | CHEMBL2331043 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL230448 | |
| PharmGKB | PA166131606 | |
| Human Metabolome Database | HMDB0257362 | |
| DrugBank | DB06201 | |
| PubChem: Thomson Pharma | 15121846 | |
| PubChem | 129228 | |
| Mcule | MCULE-6872329028 | |
| LINCS | LSM-45759 | |
| Nikkaji | J575.180B | |
| BindingDB | 50515492 | |
| EPA CompTox Dashboard | DTXSID1046506 | |
| DrugCentral | 3534 | |
| ChemicalBook | CB5972298 | |
| Guide to Pharmacology | 7470 | |
| rxnorm | BANZEL | RUFINAMIDE |
| PubChem: Drugs of the Future | 12014051 | |
| ChEBI | 134966 | |
| ZINC | ZINC000000007782 |
